Sunesis To Move Novel Cell-Cycle Inhibitor Forward In Small Cell Lung Cancer
This article was originally published in The Pink Sheet Daily
Firm believes the drug, SNS-595, could offer an improved toxicity profile over GSK's Hycamtin.
You may also be interested in...
Early results generate interest from would-be partners, company tells “The Pink Sheet” DAILY.
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.